Introducing Revvity – Expanding the boundaries of human potential through science.
All products and services previously affiliated with Oxford Immunotec are now part of Revvity.

The T-SPOT®.TB test is the only TB test with sensitivity of 98.8% and specificity above 99%.1

The T-SPOT.TB test

The T-SPOT.TB test has demonstrated sensitivity and specificity exceeding 95% and reliability in all patient groups, including the immunosuppressed1, and it does not cross-react with the bacille Calmette-Guerin (BCG) vaccine.

NICE Tuberculosis Guideline (NG 33, 2016, updated September 2019)
The National Institute of Health and Clinical Excellence (NICE) guidelines give clear recommendations for the use of Interferon Gamma Release Assays (IGRAs) for the detection of tuberculosis in a number of important patient groups. The most recent guideline was produced in 2016 with updates in 2019 and is available here.

Find out more about T-SPOT.TB here


1. Wong SH, Gao Q, Tsoi KKF, et al. Effect of immunosuppressive therapy on interferon γ release assay for latent tuberculosis screening in patients with autoimmune diseases: a systematic review and meta-analysis. Thorax. 2016;71:64–72.


Oxford Diagnostic Laboratories
are a Trading Division of Oxford Immunotec Ltd.

U.S. Headquarters | Int'l Headquarters

Labs Conducting the T-SPOT.TB Test